ESTRO37_ProgrammeBook

10:40 > Pravastatin reverses fibrosis in head and neck cancer patients: phase II clinical trial results C. Bourgier (France), S. Rivera, M.C. Vozenin, P. Boisselier, D. Azria, N. Lassau, P. Taourel, J. Bourhis, E. Deutsch, A. Aupérin 10:50 > EMT signatures as a prognostic marker for metastasis in HPV-negative HNSCC M. Van der Heijden (The Netherlands), P. Essers, M. Verheij, M. Van den Brekel, C. Vens 11:00 > Prognostic biomarkers and targets for personalization of radiotherapy of HNSCC: CD44v6 U. Schötz (Germany), M. Orth, M. Selmansberger, J. Schuster, B. Stegen, J. Hess, K. Unger, H. Zitzelsberger, C. Belka, R. Engenhart-Cabillic, K. Lauber

MONDAY 23 APRIL 2018

OC-0486

OC-0487

OC-0488

11:10 > TAM and HLA class I expression in relation to HPV and clinical outcome in head and neck cancer

D. Ou (France), J. Adam, I. Garberis, P. Blanchard, F. Nguyen, A. Levy, O. Casiraghi, P. Gorphe, I. Breuskin, F. Janot, S. Temam, J. Scoazec, E. Deutsch, Y. Tao

OC-0489

11:20 > Targeting PARP1 and the intra-S/G2 checkpoints for highly effective radiosensitization of HPV+ HNSCC T. Rieckmann (Germany), C. Busch, K. Hintelmann, T. Berenz, M. Kriegs, A. Münscher, C. Petersen, K. Rothkamm 11:30 > CRISPR-Cas9 screen of DNA damage response reveals novel radiosensitizers for head and neck cancers R. Dok (Belgium), M. Glorieux, M. Bamps, A. Sablina, S. Nuyts

OC-0490

OC-0491

PROFFERED PAPER

CL 9: Lung 10:30 - 11:45  |  AUDITORIUM Chair: C. Le Pechoux (France) Chair: S. Ramella (Italy)

10:30 > A pooled analysis of radiotherapy dose and targeting strategies for stage 3 non-small cell lung cancer S. Schild (USA), W. Fan, T. Stinchcombe, E. Vokes, S. Ramalingam, J. Bradley, K. Kelly, H. Pang, X. Wang

OC-0492

SCIENTIFIC PROGRAMME | Programme and Exhibition Guide

150